Patents Issued in February 6, 2003
  • Publication number: 20030027778
    Abstract: The present invention is directed to compositions regarding a specific mutation in estrogen receptor alpha and their use as diagnostic markers in breast tissue, such as premalignant lesions, for the development of breast cancer. More specifically, cells of breast cancer whose nucleic acid comprises the estrogen receptor alpha mutation identify the breast cancer to be an invasive breast cancer.
    Type: Application
    Filed: January 18, 2002
    Publication date: February 6, 2003
    Inventors: Suzanne Fuqua, Peter O'Connell, D. Craig Allred, Torsten A. Hopp
  • Publication number: 20030027779
    Abstract: A method is provided for inducing DNA synthesis in differentiated neurons. According to certain embodiments of the invention, a method for inducing DNA synthesis in a differentiated neuron is provided that includes obtaining a vector comprising nucleic acid encoding an E2F regulator and/or an E1A regulator, wherein the vector can be used to express the nucleic acid in a differentiated neuron, and transfecting a differentiated neuron with the vector.
    Type: Application
    Filed: January 25, 2002
    Publication date: February 6, 2003
    Applicant: Spinal Cord Society
    Inventors: Toomas Neuman, Kikuo Suda, Howard O. Nornes
  • Publication number: 20030027780
    Abstract: The present invention is related to non-parenteral multiparticulate formulations capable of transporting therapeutic, prophylactic and diagnostic agents across mucosal membranes such as gastrointestinal, buccal, nasal, rectal and vaginal. Formulations comprise a plurality of carrier particles, an agent to be delivered across a mucosal membrane, and a penetration enhancer. The drug is adhered to the surface of the carrier particle or is impregnated within by electrostatic, covalent or mechanical forces.
    Type: Application
    Filed: February 8, 2002
    Publication date: February 6, 2003
    Inventors: Gregory E. Hardee, Lloyd G. Tillman, Maria Gonzalez-Ferreiro, Rahul C. Mehta, Ching-Leou Teng
  • Publication number: 20030027781
    Abstract: This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, endothelia of the blood brain and CSF-blood barriers, glioblastomas, and lymphomas are described.
    Type: Application
    Filed: February 14, 2002
    Publication date: February 6, 2003
    Inventors: Joseph S. Heilig, Larry Gold
  • Publication number: 20030027782
    Abstract: The invention is directed to a method for treating both the early and late phases of allergic asthma by introducing naked polynucleotides which operatively encode for the asthma-initiating antigen into the host. The antigen-encoding polynucleotides are administered to host tissues which contain a high concentration of antigen presenting cells (e.g., skin and mucosa) relative to other host tissues. Expression of the asthma-initiating antigen encoding polynucleotides of the invention inside of antigen presenting cells (without substantial secretion therefrom) induces antigen tolerance while suppressing IgE antibody formation in the early phase of the disease, and also suppresses cytokine-mediated eosinophil accumulation in the late phase of the disease. Devices and compositions for use in the methods of the invention are also described.
    Type: Application
    Filed: May 13, 2002
    Publication date: February 6, 2003
    Inventors: Dennis A. Carson, Eyal Raz
  • Publication number: 20030027783
    Abstract: The present invention relates to the specific inhibition of gene expression in mammals by bringing the target into contact with double stranded RNA (dsRNA).
    Type: Application
    Filed: May 17, 2002
    Publication date: February 6, 2003
    Inventors: Magdalena Zernicka-Goetz, Florence Wianny, Martin John Evans, David Moore Glover
  • Publication number: 20030027784
    Abstract: The invention relates to low molecular weight polyethylenimines, to vectors for inserting nucleic acids into cells which contain low molecular weight polyethylenimines, and to the preparation and use of the low molecular weight polyethylenimine and the vector.
    Type: Application
    Filed: October 7, 2002
    Publication date: February 6, 2003
    Inventors: Thomas Kissel, Dagmar Fischer, Hans-Peter Elsasser, Thorsten Bieber
  • Publication number: 20030027785
    Abstract: The present invention is directed to a method of altering the amount or composition of synovial fluids secreted from joints in a subject in need of such treatment. The method comprises administering to a subject a pharmaceutical composition comprising a P2Y purinergic receptor agonist in an amount effective to alter the amount or composition of synovial fluids. The P2Y purinergic receptor agonist is administered in an amount effective to stimulate secretion of synovial fluid, lubricin, hyaluronic acid, or surface-active phospholipids; to enhance joint lubrication; or to treat osteoarthritis. The pharmaceutical compositions useful in the present invention comprise a P2Y purinergic receptor agonist of Formula I and include, but are not limited to: uridine-, adenosine-, cytidine-5′-di- or triphosphates, dinucleoside polyphosphates, and analogs thereof. The invention is useful for treating conditions associated with reduced joint lubrication and joint stiffness, such as osteoarthritis.
    Type: Application
    Filed: June 25, 2002
    Publication date: February 6, 2003
    Inventors: Matthew S. Cowlen, Benjamin R. Yerxa, Arthur C. Jones, Edward G. Brown
  • Publication number: 20030027786
    Abstract: Pharmaceutical compositions that contain a lipase inhibitor having a melting point ≧37° C., a sucrose fatty acid ester wherein the sucrose fatty acid ester is a mono-, di-, tri- or tetra-ester, and optionally one or more pharmaceutically acceptable excipients, are useful for treatment of obesity.
    Type: Application
    Filed: May 23, 2002
    Publication date: February 6, 2003
    Inventors: Karsten Maeder, Rainer Eugen Martin, Susanne Raab, Lukas Christoph Scheibler, Thomas Schindler, Marco Schroeder
  • Publication number: 20030027787
    Abstract: New crosslinked polysaccharides useful as absorbents or superabsorbents alone or in a mixture are obtained by reacting polysaccharides (preferably containing carboxylates groups) with at least one crosslinker selected in the group constituted by activated polyethylene glycols such as for example halogenated (Cl, Br, I), mesylated, tosylated, or triflated activated polyethylene glycols.
    Type: Application
    Filed: November 9, 2001
    Publication date: February 6, 2003
    Applicant: GROUP LYSAC INC./LYSAC GROUP INC.
    Inventors: Claude Couture, David Bergeron, Frederic Picard
  • Publication number: 20030027788
    Abstract: Compounds that are modified polysaccharides having pendant aldehyde functionalities are disclosed. Each of the aldehyde functionalities is attached through a linker to a position corresponding to a hydrogen atom of a different hydroxyl group of unmodified polysaccharide. Also disclosed is a method for introducing an amine-reactive functionality into a dextran. The method comprises (a) reacting the dextran with an alkylating agent having a functionality that reacts with an hydroxyl group of the dextran thereby forming an alkylated dextran wherein the alkylating agent has an olefin group and (b) treating the alkylated dextran to convert the olefin group to an amine-reactive functionality. A polysaccharide can be conjugated to a biomolecule by carrying out the above method and reacting the amine-reactive functionality with an amine functionality on the biomolecule to produce polysaccharide conjugated to the biomolecule.
    Type: Application
    Filed: July 2, 2002
    Publication date: February 6, 2003
    Inventors: Rajendra Singh, Harshvardhan Mehta
  • Publication number: 20030027789
    Abstract: The present invention provides a sodium ion absorption inhibitor comprising a metal salt, other than a sodium salt, of a cellulose derivatives represented by the following formula (I) as an active ingredient, whereby absorption of salt excessively present into a living body is effectively inhibited and salt excessively present is excreted outside the body positively and safely. Furthermore, the present invention provides an agent for preventing and treating diseases caused by excessive salt ingestion or diseases in which restriction on salt ingestion is required, comprising the same as an active ingredient, and foods comprising the same.
    Type: Application
    Filed: July 12, 2002
    Publication date: February 6, 2003
    Inventors: Ippei Yamaoka, Kyota Sakai, Kozo Asagi, Takuzi Uesako, Kinzi Hashimoto, Masaru Kobayashi, Tsutomu Uehara
  • Publication number: 20030027790
    Abstract: There is provided a pharmaceutical preservative free composition suitable for topical administration to an eye, the composition comprising (a) an oxazolidinone antimicrobial drug, for example linezolid, in a therapeutically or prophylactically effective drug concentration that is above the practical limit of solubility of the drug in a substantially isotonic aqueous solution at a physiologically compatible pH, and (b) a pharmaceutically acceptable cyclodextrin compound in a concentration sufficient to maintain the drug-in solution at such a drug concentration. The composition is particularly useful for the treatment and/or prevention of eye infections due to gram positive bacteria.
    Type: Application
    Filed: February 22, 2002
    Publication date: February 6, 2003
    Inventors: Satish K. Singh, Lisa A. Adams, Paramita Bandyopadhyay, Syed Hasan, Leslie C. Hawley, Sandra M. Sims
  • Publication number: 20030027791
    Abstract: Compositions and methods are provided for reducing adverse reactions as a result of parenteral administration of certain phenothiazine derivatives such as promethazine hydrochloride. The active compound may be admixed with an effective amount of one or more cyclodextrin derivatives, and if desired, one or more non-ionic surfactants such as the partial esters of sorbitol and the polyoxyethylene oxides of long chain fatty acids such as the polysorbates.
    Type: Application
    Filed: June 26, 2002
    Publication date: February 6, 2003
    Applicant: Wyeth
    Inventor: Jianwei Yu
  • Publication number: 20030027792
    Abstract: The present invention relates to the use of certain siloxanes and mixtures thereof in the control of arthropods such as insects and arachnids, and in particular ectoparasites, such as head lice.
    Type: Application
    Filed: March 15, 2002
    Publication date: February 6, 2003
    Inventor: Jayne Ansell
  • Publication number: 20030027793
    Abstract: This invention provides the use of a silicone-based transdermal therapeutic system having an area of 10 to 40 cm2 and containing 0.1 to 3.15 mg/cm2 of Rotigotine as active ingredient, for the preparation of an anti-Parkinson medicament which effects an improvement, compared to a placebo treatment, of the condition of human Parkinson patients, measured according to the Unified Parkinson's Disease Rating Scale (UPDRS) parts II and III, of 2 units or more following administration for a time period of at least 7 weeks.
    Type: Application
    Filed: May 7, 2002
    Publication date: February 6, 2003
    Inventors: Thomas Lauterback, Walter Muller, Dietrich Wilhelm Schacht, Hans-Michael Wolff
  • Publication number: 20030027794
    Abstract: N-Heterocyclic derivatives of the formula (I): 1
    Type: Application
    Filed: April 12, 2002
    Publication date: February 6, 2003
    Applicant: Berlex Laboratories, Inc.
    Inventors: Damian O. Arnaiz, John J. Baldwin, David D. Davey, James J. Devlin, Roland Ellwood Dolle, Shawn David Erickson, Kirk McMillan, Michael M. Morrissey, Michael H. J. Ohlmeyer, Gonghua Pan, Vidyadhar Madhav Paradkar, John Parkinson, Gary B. Phillips, Bin Ye, Zuchun Zhao
  • Publication number: 20030027795
    Abstract: This invention provides compounds of Formula I having the structure 1
    Type: Application
    Filed: July 25, 2002
    Publication date: February 6, 2003
    Applicant: Wyeth
    Inventors: Fuk-Wah Sum, Michael Sotirios Malamas
  • Publication number: 20030027796
    Abstract: Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.
    Type: Application
    Filed: August 23, 2002
    Publication date: February 6, 2003
    Applicant: Lahive & Cockfield, LLP
    Inventors: Walter A. Szarek, Xianqi Kong, Gregory R.J. Thatcher, Boris Gorine
  • Publication number: 20030027797
    Abstract: This invention provides compounds of Formula I having the structure 1
    Type: Application
    Filed: September 5, 2002
    Publication date: February 6, 2003
    Applicant: Wyeth
    Inventors: Fuk-Wah Sum, Baihua Hu
  • Publication number: 20030027798
    Abstract: The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.
    Type: Application
    Filed: September 21, 2001
    Publication date: February 6, 2003
    Inventors: Pascal Druzgala, Peter G. Milner, Jurg R. Pfister
  • Publication number: 20030027799
    Abstract: The present invention provides a novel method for treating a patient with cancer comprising administering to the patient a therapeutically effective amount of cisplatin and a compound having the formula I: 1
    Type: Application
    Filed: March 28, 2002
    Publication date: February 6, 2003
    Applicant: Shire BioChem Inc.
    Inventor: Jacques Jolivet
  • Publication number: 20030027800
    Abstract: The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.
    Type: Application
    Filed: March 19, 2001
    Publication date: February 6, 2003
    Inventors: Duane D. Miller, Gabor Tigyi, James T. Dalton, Vineet M. Sardar, Don B. Elrod, Huiping Xu, Daniel L. Baker, Dean Wang, Karoly Liliom, David J. Fischer, Tamas Virag, Nora Nusser
  • Publication number: 20030027801
    Abstract: Methods are provided for treatment of eye disorders and injury, including methods for treatment of reduced flow of blood or other nutrients to retinal tissue and/or optic nerve, methods for treatment of retinal ischemia and trauma and methods for treatment for optic nerve injury/damage.
    Type: Application
    Filed: January 29, 2002
    Publication date: February 6, 2003
    Inventor: Robert N. McBurney
  • Publication number: 20030027802
    Abstract: This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing antipsychotic-induced weight gain. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing AP-induced weight gain in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
    Type: Application
    Filed: July 22, 2002
    Publication date: February 6, 2003
    Applicant: Corcept Therapeutics, Inc.
    Inventors: Joseph K. Belanoff, Alan F. Schatzberg
  • Publication number: 20030027803
    Abstract: The invention is of both a composition and method for inhibiting the proliferation of cancerous cells, and brain and nervous system cells in particular. The composition is, and the method is based on the use of a composition consisting (among active ingredients) substantially of 2-methoxyestradiol and/or one of a number of analogues thereof. The present inventors have demonstrated beyond serious doubt that these compounds have a pronounced effect in inhibiting the proliferation of cancerous brain and nervous system cells and, therefore, provide a desperately needed stepping stone for advancing toward meaningful treatment of brain and nervous system cancer.
    Type: Application
    Filed: February 6, 2001
    Publication date: February 6, 2003
    Applicant: Oncology Sciences Corporation
    Inventors: Thomas J. Slaga, Addanki P. Kumar, William Alworth
  • Publication number: 20030027804
    Abstract: The present invention relates to methods of treating, preventing, or reducing the risk of developing a male or female menopause disorder or symptom in a mammal by administering to the mammal a sex hormone binding globulin synthesis inhibiting agent and one or more steroids, including, for example, an androgen or an estrogen; to combinations for treating, preventing or reducing the risk of developing a male or female menopause disorder or symptom in a mammal; and to compositions for treating, preventing, or reducing the risk of developing a male or female menopause disorder or symptom in a mammal, where the composition comprises a sex binding globulin synthesis inhibiting agent and one or more steroids, including, for example, an androgen or an estrogen.
    Type: Application
    Filed: June 27, 2001
    Publication date: February 6, 2003
    Inventor: Roland Gerritsen van der Hoop
  • Publication number: 20030027805
    Abstract: This invention discloses a method of administering 1,4-androstadienedione as a means of increasing boldenone levels in humans. As men age, a decline in androgenic hormone levels is typically noted, possibly resulting in muscle mass, bone density and energy loss. Various methods have therefore been developed to supplement androgens for men with declining levels. This invention is an improvement over the previously suggested steroid precursors, in that androstadienedione displays superior oral activity. This may be a very advantageous trait for men seeking the an orally active form of androgen replacement.
    Type: Application
    Filed: July 25, 2002
    Publication date: February 6, 2003
    Inventor: William Charles Llewellyn
  • Publication number: 20030027806
    Abstract: The present invention provides synthetic methods and compositions for treatment of autoimmune and anti-inflammatory disorders comprising administering an effective amount of a derivative of triptolide alone or in combination or alternation with other anti-autoimmune or anti-inflammatory compounds.
    Type: Application
    Filed: October 2, 2001
    Publication date: February 6, 2003
    Inventors: Susheng Wang, Dennis C. Liotta, James P. Snyder, Hariharan Venkatesan
  • Publication number: 20030027807
    Abstract: The present invention relates to compounds of the formula I
    Type: Application
    Filed: May 13, 2002
    Publication date: February 6, 2003
    Applicant: Genentech, Inc. and Hoechst Aktiengesellschaft
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Anuschirwan Peyman, Jochen Knolle, Jean-Marie Ruxer, Denis Carniato, Jean-Michel Lefrancois, Thomas Richard Gadek, Robert McDowell
  • Publication number: 20030027808
    Abstract: The present invention is concerned with combinations of a farnesyl transferase inhibitor and a platinum compound for inhibiting the growth of tumor cells and useful in the treatment of cancer.
    Type: Application
    Filed: August 28, 2002
    Publication date: February 6, 2003
    Inventors: Peter Albert Palmer, Ivan David Horak
  • Publication number: 20030027809
    Abstract: An objective of the present invention is to provide carbapenem derivatives which have potent antibiotic activity against MRSA, PRSP, Influenzavirus, and &bgr;-lactamase-producing bacteria and are stable against DHP-1.
    Type: Application
    Filed: July 25, 2002
    Publication date: February 6, 2003
    Inventors: Yuko Kano, Takahisa Maruyama, Yumiko Sambongi, Kazuhiro Aihara, Kunio Atsumi, Kastuyoshi Iwamatsu, Takashi Ida
  • Publication number: 20030027810
    Abstract: The invention provides nicotine receptor agonists of formula I: 1
    Type: Application
    Filed: November 30, 2001
    Publication date: February 6, 2003
    Applicant: Regents of the University of Minnesota
    Inventor: S. Mbua Ngale Efange
  • Publication number: 20030027811
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Application
    Filed: September 6, 2002
    Publication date: February 6, 2003
    Applicant: Allergan Sales, Inc.
    Inventors: Orest Olejnik, Edward D.S. Kerslake
  • Publication number: 20030027812
    Abstract: The present invention relates to lactam derivatives of the formula 1
    Type: Application
    Filed: August 15, 2002
    Publication date: February 6, 2003
    Applicant: Pfizer Inc.
    Inventor: Harry R. Howard
  • Publication number: 20030027813
    Abstract: The present invention provides a composition comprising synergistic amounts of a compound of the formula (I) 1
    Type: Application
    Filed: June 3, 2002
    Publication date: February 6, 2003
    Inventors: Stefan Dutzmann, Christoph Erdelen, Wolfram Andersch, Heinz-Wilhelm Dehne, Jurgen Hartwig, Klaus Stenzel, Wolfgang Kramer
  • Publication number: 20030027814
    Abstract: A bis(5-aryl-2-pyridyl) compound represented by formula (1) or a salt thereof: 1
    Type: Application
    Filed: June 29, 2001
    Publication date: February 6, 2003
    Applicant: Kowa Co., Ltd.
    Inventors: Hiroyuki Ishiwata, Seiichi Sato, Mototsugu Kabeya, Soichi Oda, Makoto Suda, Manabu Shibasaki
  • Publication number: 20030027815
    Abstract: The present invention provides novel tricyclic benzodiazepine carboxamides compounds and methods and pharmaceutical compositions utilizing them for the treatment and/or prevention and/or suppression of disorders which may be remedied or alleviated by oxytocin antagonist activity, including prevention and/or suppression suppression of preterm labor, suppression of labor at term prior to caesarean delivery, and for the treatment of dysmenorrhea. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and may be useful in the prevention and treatmraent of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.
    Type: Application
    Filed: April 10, 2002
    Publication date: February 6, 2003
    Applicant: Wyeth
    Inventors: Amedeo Arturo Failli, John Paul Dusza, Eugene John Trybulski, Kevin Anthony Memoli, Jay Scott Shumsky
  • Publication number: 20030027816
    Abstract: The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.
    Type: Application
    Filed: May 1, 2002
    Publication date: February 6, 2003
    Inventors: Douglas J. Allen, Kurt D. Dekemper, Thomas H. Ferguson, Stuart J. Garvin, Linda C. Murray, Norman D. Brooks, Charles A. Bunnell, Snehlata S. Mascarenhas, Sharon L. Shinkle, Barry A. Hendriksen, David E. Tupper, Manuel V. Sanchez-Felix
  • Publication number: 20030027817
    Abstract: The invention provides methods and compositions for the treatment of Bipolar Disorder, Bipolar Depression or Unipolar Depression, all with or without psychotic features. This method employs a compound having activity as an atypical antipsychotic and a serotonin reuptake inhibitor.
    Type: Application
    Filed: June 7, 2002
    Publication date: February 6, 2003
    Inventor: Gary Dennis Tollefson
  • Publication number: 20030027818
    Abstract: A method of inducing apoptotic death of a neoplastic cell, whereby the neoplastic cell is contacted with an apoptosis-inducing amount of a methylol-containing compound. This method is useful for treating both primary and metastatic cancers. A preferred embodiment includes administering a :4 methylol transfer agent to the mammal, at a total daily dose of from about 2 g to about 60 g, the administration including at least two dosing cycles, each dosing cycle including an infusion phase of about 1 to 8 days, and a non-administration phase of about 1 to 14 days. Another embodiment includes treating liver cancer by administration of a solution of a methylol transfer agent directly to the liver via a hepatic vessel.
    Type: Application
    Filed: March 29, 2002
    Publication date: February 6, 2003
    Inventors: H. Paul Redmond, Hanns Moehler, Ruediger Stendel, Rolf W. Pfirrmann
  • Publication number: 20030027819
    Abstract: &bgr;-sheet mimetics and methods relating to the same are disclosed. The &bgr;-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a &bgr;-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase, transcription factor and/or protein-protein binding interaction.
    Type: Application
    Filed: September 21, 2001
    Publication date: February 6, 2003
    Applicant: Molecumetics Ltd.
    Inventors: Maher N. Qabar, Michael K. McMillan, Michael S. Kahn, John E. Tulinsky, Cyprian O. Ogbu, Jessymol Mathew
  • Publication number: 20030027820
    Abstract: Provided, among things, is a method of treating or ameliorating an indication of the invention in an animal, including a human, comprising administering an effective amount of a compound of the formula IA and or IB: 1
    Type: Application
    Filed: May 30, 2002
    Publication date: February 6, 2003
    Applicant: Alteon, Inc.
    Inventor: Martin Gall
  • Publication number: 20030027821
    Abstract: The use of a compound comprising formula (I): 1
    Type: Application
    Filed: July 6, 2001
    Publication date: February 6, 2003
    Inventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
  • Publication number: 20030027822
    Abstract: The invention provides sodium channel modulating compounds of formula I: 1
    Type: Application
    Filed: August 30, 2001
    Publication date: February 6, 2003
    Inventors: Jason P. Chinn, Seok-Ki Choi, Paul R. Fatheree, Daniel Marquess, S. Derek Turner
  • Publication number: 20030027823
    Abstract: A compound of formula (I) 1
    Type: Application
    Filed: August 21, 2001
    Publication date: February 6, 2003
    Inventors: Enzo Cereda, Luciano Maiocchi, Alessandro Brambilla, Ettore Giraldo, Eugenia Monferini, Giovanni Battista Schiavi
  • Publication number: 20030027824
    Abstract: The use of a compound of formula (I) wherein R1 is H; C1-C3 alkyl; C1-C3 perfluomalkyl; or C3-C5 cycloalkyl; R2 is H; optionally substituted C1-C6 alkyl; C1-C3 pefluoroalkyl; or C3-C6 cycloalkyl; R3 is optionally substituted C1-C6 alkyl; C1-C6 perfluoroalkyl; C3-C5 cycloalkyl; C3-C6 alkenyl; or C3-C6 alkynyl; R4 is optionally substituted C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkanoyl, (hydroxy)C2-C4 alkyl or (C2-C3 alkoxy)C1-C2 alkyl; CONR5R6; CO2R7; halo; NR5R6; NHSO2NR5R6; NHSO2R8; SO2NR9R10; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R5 and R6 are each independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R11)-piperazinyl or imidazolyl group; R7 is H or C1-C4 alkyl; R8 is optionally substituted C1-C3 alkyl; R9 and R10 together with the nitrogen atom to which they are attached form an optionally substitute
    Type: Application
    Filed: July 24, 2002
    Publication date: February 6, 2003
    Inventors: Peter Ellis, Nicholas Kenneth Terrett
  • Publication number: 20030027825
    Abstract: This invention is concerned with a novel polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)-ethoxy)-3- (S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine which is a tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic form has advantages over the other known forms of 2-(R)-(1-(R)-(3,5-bis(trifluoro-methyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations.
    Type: Application
    Filed: August 12, 2002
    Publication date: February 6, 2003
    Applicant: Merck & Co. Inc.
    Inventors: Louis Crocker, James Mccauley
  • Publication number: 20030027826
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CERP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
    Type: Application
    Filed: December 12, 2001
    Publication date: February 6, 2003
    Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Publication number: 20030027827
    Abstract: Disclosed is the compound (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and pharmaceutically acceptable salts and solvates thereof, methods for preparing them, pharmaceutical compositions comprising them, and processes for their preparation; also disclosed is a method of treating depression, attention deficit hyperactivity disorder (ADHD), obesity, migraine, sexual dysfunction, Parkinson's disease, Alzheimer's disease, or addiction to cocaine or nicotine-containing (especially tobacco) products using such compound, salts, solvates or compositions.
    Type: Application
    Filed: May 17, 2002
    Publication date: February 6, 2003
    Inventors: Toby Broom, Monica Delpogetto, Richard Atkins, Alan Negus, Paul William Oxley